How are weight-loss drugs reshaping UK grocery spending? The impact tops £1 billion


Mounjaro and Wegovy are changing British shopping habits, with households using weight-loss drugs spending less on alcohol and crisps while buying more frozen ready meals

The growing popularity of weight-loss drugs in the UK is taking a bite out of grocery spending. Households with at least one user of medicines such as Mounjaro and Wegovy spent more than £1 billion less than expected, according to new research.

The findings point to how the growing adoption of GLP-1 medicines is changing consumer behaviour, with users buying less alcohol and fewer snacks while shifting towards convenient, portion-controlled food options.

Consumer research company Worldpanel by Numerator said on Thursday that British households with at least one GLP-1 user spent more than £1 billion less on groceries in the year after adoption compared with households without a user of the drugs.

The estimated reduction works out to £389 a year for each household using the medicines.

Weight-loss drug use is rising in UK households

The proportion of British households with at least one GLP-1 user increased from 6.3 per cent in February 2026 to 8.5 per cent in August, according to Worldpanel.

The pace of adoption is also accelerating. The number of people using GLP-1 injections and pills in the six months to August rose almost as much as it had during the entire preceding year.

businessMore from Business

Worldpanel estimates that usage could exceed 10 per cent of British households in 2027.

The expansion is not limited to injectable treatments. Although regulatory approval for pill-based GLP-1 treatments came only in June, pills already accounted for 11.2 per cent of UK GLP-1 users.

Men are also becoming a larger part of the user base. They accounted for 32 per cent of GLP-1 users in August, compared with 23 per cent in February.

The findings are based on Worldpanel’s survey data tracking household purchases, which drew on a total sample of 9,629 British households.

Alcohol and crisps lose ground as eating habits change

The impact of weight-loss drugs is becoming visible in the types of products consumers buy.

Worldpanel found that spending on alcohol and crisps among households with GLP-1 users had fallen 15 per cent more than in households without users.

The trend suggests that the medicines could have implications for food and beverage companies whose businesses depend on frequent purchases of snacks, alcohol and other discretionary products.

GLP-1 medicines work by mimicking a hormone involved in regulating appetite and blood sugar. They can increase feelings of fullness, reduce hunger and slow the movement of food through the stomach.

As a result, users may consume smaller portions or change their food preferences, potentially affecting demand for products that traditionally form part of regular grocery purchases.

At the same time, some food categories are benefiting from changing consumption patterns. Volume sales of frozen ready meals have increased 30 per cent among households with GLP-1 users, Worldpanel said.

The rise points to growing demand for convenient, portion-controlled food options as consumers adjust their eating habits.

Why the trend matters for food companies and retailers

The findings highlight how the growing adoption of weight-loss medicines could extend beyond the pharmaceutical industry and influence the wider consumer economy.

For supermarkets, food manufacturers and beverage companies, the potential impact lies in changing demand across product categories rather than simply a reduction in overall grocery spending.

If adoption continues to rise, companies may need to reassess product sizes, packaging, pricing and the mix of products they offer.

The shift could also create opportunities for businesses selling smaller portions, high-protein products and convenient meal options.

However, the £1 billion figure represents spending that was lower than expected compared with households without GLP-1 users. It should not be interpreted as a direct £1 billion decline in total UK grocery sales attributable exclusively to the medicines.

With GLP-1 use expected to cross 10 per cent of British households in 2027, the implications for supermarkets and food companies could become increasingly difficult to ignore.

  • Related Posts

    Can China’s ByteDance access OpenAI models through Microsoft? US lawmakers want answers

    A reported $500 million Azure deal could give ByteDance access to OpenAI models, prompting US lawmakers to question Microsoft’s role in China’s AI ambitions A reported $500 million deal between…

    Continue reading
    Anthropic raises $81.3 billion in record IPO, overtakes SpaceX’s stock market debut: Report

    Anthropic’s $81.31 billion IPO surpasses SpaceX’s record-setting offering, marking a milestone for the AI industry. But nearly $901 billion in computing commitments, rising infrastructure costs and questions over profitability pose…

    Continue reading